Prophylaxis with recombinant factor IX Fc fusion protein reduces the risk of bleeding and delays time to first spontaneous bleed event in previously untreated patients with haemophilia B: A post hoc analysis of the PUPs B‐LONG study
European Journal of Haematology · 2024
DOI: 10.1111/ejh.14252 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Beatrice Nolan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Haematology Department, Children's Health Ireland at Crumlin, Dublin, Republic of Ireland. Hauptthemen laut MEDLINE: Factor IX, Hemophilia B, Hemorrhage, Immunoglobulin Fc Fragments. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objectives
Haemophilia B (HB), characterised by deficient factor IX (FIX), leads to spontaneous bleeds. Severe cases require prophylactic FIX replacement. This post hoc analysis assessed the first spontaneous bleeds among previously untreated patients (PUPs) with HB treated with recombinant FIX Fc fusion protein (rFIXFc) (NCT02234310) to identify factors influencing bleeds.
Methods
Subjects included paediatric PUPs with HB (≤2 IU/dL endogenous FIX). Analyses described treatment patterns (on demand [OD] vs. prophylaxis) and prophylaxis type (started on vs. switched to prophylaxis). Kaplan–Meier analyses assessed the time to first spontaneous bleed, including median time to event and fitting models with predictors for treatment regimen and/or baseline age.
Results
PUPs B‐LONG enrolled 33 subjects. Baseline age did not influence the time to first spontaneous bleed for any rFIXFc regimen. Those who started on prophylaxis with rFIXFc ( n = 11), compared with those treated OD ( n = 22), had an extended time to first spontaneous bleed. Starting prophylaxis afforded a 93% reduced risk of first spontaneous bleed versus starting OD (hazard ratio [95% confidence interval]: 0.071 [0.009–0.592]) ( p = .015). Conclusion rFIXFc prophylaxis, particularly starting early, reduced the risk of bleeding and delayed time to first spontaneous bleed compared with rFIXFc OD. Hence, initial treatment regimens impact bleed patterns in paediatric PUPs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Haematology Department, Children's Health Ireland at Crumlin, Dublin, Republic of Ireland.
- National Bleeding Disorders Foundation, New York City, New York, USA.
- Yale University School of Medicine, New Haven, Connecticut, USA.
- Sanofi, Waltham, Massachusetts, USA.
- Sobi, Stockholm, Sweden.
- Sanofi, Cambridge, Massachusetts, USA.
ORCID-Profile: Beatrice Nolan, Antoine Rauch
Zitieren
APA
Nolan, B., Recht, M., Rendo, P., Falk, A., Foster, M., Casiano, S., Rauch, A., & Shapiro, A. (2024). Prophylaxis with recombinant factor IX Fc fusion protein reduces the risk of bleeding and delays time to first spontaneous bleed event in previously untreated patients with haemophilia B: A post hoc analysis of the PUPs B‐LONG study. European Journal of Haematology. https://doi.org/10.1111/ejh.14252
Vancouver
Nolan B, Recht M, Rendo P, Falk A, Foster M, Casiano S, et al. Prophylaxis with recombinant factor IX Fc fusion protein reduces the risk of bleeding and delays time to first spontaneous bleed event in previously untreated patients with haemophilia B: A post hoc analysis of the PUPs B‐LONG study. European Journal of Haematology. 2024. doi:10.1111/ejh.14252
BibTeX
@article{Nolan2024,
author = {Nolan, Beatrice and Recht, Michael and Rendo, Pablo and Falk, Aletta and Foster, Meredith and Casiano, Sandra and Rauch, Antoine and Shapiro, Amy},
title = {Prophylaxis with recombinant factor IX Fc fusion protein reduces the risk of bleeding and delays time to first spontaneous bleed event in previously untreated patients with haemophilia B: A post hoc analysis of the PUPs B‐LONG study},
journal = {European Journal of Haematology},
year = {2024},
doi = {10.1111/ejh.14252}
}
EUVIMED